Sanofi
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.82 | 41 |
| immunology | ×1.50 | 5 |
| rareDisease | ×1.50 | 5 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.50 | 20 |
| phase 2 | ×0.73 | 15 |
| phase 3 | ×0.89 | 11 |
| preclinical | ×1.43 | 5 |
| phase 1 | ×0.76 | 4 |
| discovery | ×0.99 | 3 |
Strategy profile
Based on 15 disclosed transactions, Sanofi concentrates its licensing activity in Immunology, Hematology, and Oncology. Sanofi pays a 1.08x premium over market median, with the strongest premiums in Immunology (1.50x). Their most common deal structure is License, with an average disclosed value of $1.9B. Most recent activity: 2026.
Premium by therapeutic area
How Sanofi pays relative to peer medians in each TA
Pipeline coverage & gaps
Sanofi has disclosed activity in 3 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 8 | $124M | $1.2B |
| Acquisition | 4 | $1.7B | $3.5B |
| Collaboration | 3 | $130M | $1.7B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | rovadicitinib | Chia Tai Tianqing | inflammation/autoimmune | unknown | — | $1.5B |
| 2026 | KT-485 (SAR447971) | Kymera Therapeutics | hidradenitis suppurativa and other immuno-inflammatory diseases | phase_1 | — | $975M |
| 2026 | Blueprint Medicines portfolio | Blueprint Medicines | — | unknown | — | $9.0B |
| 2026 | NanoDisc platform | Evoq Therapeutics | autoimmune disorders (celiac disease, Type 1 diabetes, MOG antibody disease, rheumatoid arthritis, lupus) | preclinical | — | $500M |
| 2026 | AXPAXLI | Ocular Therapeutix | wet AMD | phase_3 | — | $1.0B |
| 2026 | rovadicitinib | Chia Tai Tianqing Pharmaceutical Group | myelofibrosis | approved | $135M | $1.5B |
| 2026 | rovadicitinib | Sino Biopharm (Chia Tai Tianqing) | — | unknown | $135M | $1.5B |
| 2026 | rovadicitinib | Sino Biopharmaceutical | chronic graft-versus-host disease (cGVHD) | phase_2 | $135M | $1.5B |
| 2026 | Rovadicitinib | Chia Tai Tianqing Pharmaceutical Group / Sino Biopharm | graft-versus-host disease (GVHD) | unknown | $135M | $1.5B |
| 2026 | — | Earendil Labs | autoimmune | discovery | $160M | $2.6B |
| 2025 | HEPLISAV-B; Z-1018 shingles vaccine | Dynavax Technologies | vaccines / immunology | approved | $2.2B | $2.2B |
| 2025 | ADEL-Y01 | ADEL | Alzheimer's disease | unknown | $80M | $1.0B |
| 2025 | Deep B-cell depletion platform (DR-0201 and additional candidates) | Dren Bio | autoimmune diseases (B-cell depletion) | unknown | $100M | $1.7B |
| 2025 | Molecular Clamp RSV/hMPV vaccine | Vicebio | RSV and hMPV | unknown | $1.1B | $1.6B |
| 2025 | gusacitinib | Libertas Bio (Formation Bio subsidiary) | chronic hand eczema | unknown | — | $632M |
How this is computed
For each Sanofi deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 58 disclosed deal premiums vs. peer medians. Raw premium 1.079, clamped to [0.7, 1.5].